Navigation Links
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Date:9/18/2007

More than 10 data presentations demonstrate the safety and activity of

MYCAMINE as an antifungal agent

CHICAGO, Sept. 18 /PRNewswire/ -- New data from a pooled analysis of 17 clinical studies demonstrate that MYCAMINE(R) (micafungin sodium) for injection offers a favorable clinical safety profile in hospitalized patients of all ages with serious, underlying diseases with immunosuppressed status. These studies, which represent the largest published safety data for an antifungal medicine to date, looked at more than 3,000 patients who received at least one dose of MYCAMINE, with median treatment lasting 18 days. Importantly, the investigators attribute few adverse events to treatments, even in longer periods of exposure. Comparative study data showed MYCAMINE had a similar safety profile to fluconazole, caspofungin and liposomal amphotericin B. These data were presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

MYCAMINE is approved for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the prophylaxis of Candida infections and in patients undergoing hematopoietic stem cell transplantation.

"While current therapies may adequately treat many patients, drug safety is particularly critical in certain populations, particularly elderly patients," said Oliver Cornely, MD, University Hospital of Cologne, Germany. "These findings should be reassuring to physicians, in that they shed light on the safety and tolerability of MYCAMINE which has been studied more than any other echinocandin."

In addition to this analysis, 11 other MYCAMINE abstracts were accepted for presentation at this year's ICAAC meeting. When looked at together, the data provide further insight on MYCAMINE and its activity, demonstrating its value as an effective treatment for invasive fungal infections, compared to other drugs in its class.

"Astellas has a history of commitment to the development of medicines that can change the way healthcare providers treat infectious disease," said Nkechi Azie, MD, Medical Director, Medical Sciences, Astellas. "We are proud to see this number of micafungin studies at ICAAC and will continue to work collectively in the anti-infective community toward optimal treatment options for these patients."

Susceptibility Testing of Breakpoints with MYCAMINE

Results from multiple studies were presented at ICAAC, illustrating the benefits of MYCAMINE in various populations and its activity as an antifungal agent. Of the presented abstracts, the following is noteworthy as the first proposing susceptibility breakpoints of echinocandins, specifically MYCAMINE:

A Proposal for an Antifungal Susceptibility Testing (AST) Breakpoint of Micafungin and Candida: Integration of AST Surveys and Correlation with Clinical Outcomes

In this study, investigators looked at two large, well-known medical databases to determine if candida isolates are more likely to be susceptible or resistant when exposed to MYCAMINE. The survey included more than 400 patients and 5700 isolates. The analysis found candida isolates are more likely to be susceptible to MYCAMINE.

About the Safety Analysis

This pooled analysis included data from 17 clinical trials of MYCAMINE conducted between 1998 and 2006, and looked at 3,028 patients from all age groups with severe and life-threatening underlying conditions, with approximately half of patients undergoing transplants or being treated for cancer. Patients in clinical studies with MYCAMINE have complex underlying conditions, such as cancer, HIV and hematopoetic stem cell transplantation and complications such as bacterial sepsis. Data are from 17 clinical studies in patients who received at least a single dose of MYCAMINE.

Across all age groups, few adverse events were considered by the investigators to be treatment related, and no adverse events showed an increase incidence with a longer duration of exposure to MYCAMINE. No trends were seen with analysis of adverse events. Shifts in hepatic and renal laboratory values during treatment with MYCAMINE were consistent with the underlying condition of patients.

About MYCAMINE

MYCAMINE is a member of a newer class of antifungal agents, the echinocandins. MYCAMINE inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida.

Important Safety Information

MYCAMINE is contraindicated in patients with hypersensitivity to any component of this product.

Isolated cases of serious hypersensitivity (anaphylaxis and anaphylactoid) reactions (including shock) have been reported in patients receiving MYCAMINE.

Isolated cases of clinically significant hepatic dysfunction, hepatitis, worsening hepatic failure, renal dysfunction, acute renal failure, hemolysis, or hemolytic anemia have occurred in some patients who have received MYCAMINE. Patients who develop these conditions, or abnormal liver or renal function tests, should be monitored for worsening function and evaluated for risk/benefit of continuing MYCAMINE therapy.

Adverse events with MYCAMINE included mental confusion and possible histamine-mediated symptoms (including rash, pruritus, facial swelling, and vasodilatation).

About Astellas Pharma US, Inc.

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the U.S., Astellas markets products in the areas of immunology, urology, anti-infectives, cardiovascular and dermatology. For more information about Astellas Pharma US, Inc., please visit our website at http://www.astellas.com/us.

Media Contacts:

Cohn & Wolfe

Lindsey Minella

312-416-7728

Lindsey_minella@cohnwolfe.com

Astellas Pharma US Inc.

Corporate Communications

Maribeth Landwehr

847-317-8988

maribeth.landwehr@us.astellas.com


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Urinalysis Analyzers: Large Capabilities in Every Size Device
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
6. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
7. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
8. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
9. Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Managing Preanalytical Processes for Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The report forecasts the global optical transceiver ... 2016-2020. The report covers the present scenario and ... To calculate the market size, the report considers the revenue generated ...
(Date:12/9/2016)... Dec. 9, 2016  Harmar Mobility, LLC announced today that Steven ... of the Board of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... ... Mr. Dawson,s executive career includes ... across a variety of industries. He brings to the company deep ...
(Date:12/9/2016)... Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... of Physiocrine-based therapeutics to address severe, rare diseases, today announced that ... BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel ... 14, 2016, at 4:20 p.m. ET. About aTyr ... aTyr ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, ... announced today that a new solution for Emergency Departments (ED) has been added ... space in Emergency Department examination rooms, and with a simplified pallet of information ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... Plainsboro, NJ (PRWEB) , ... December 08, 2016 , ... ... patients, cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts ... In making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):